Answers are grounded in this paper and cite their sources.
This randomized trial evaluates new PET probes for 5-HT3 receptors, indicating limited imaging utility.
Serotonin-gated ionotropic 5-HT 3 receptors are the major pharmacological targets for antiemetic compounds. Furthermore, they have become a focus for the treatment of irritable bowel syndrome (IBS) and there is some evidence that pharmacological modulation of 5-HT 3 receptors might alleviate symptoms of other neurological disorders. Highly selective, high-affinity antagonists, such as granisetron (Kytril) and palonosetron (Aloxi), belong to a family of drugs (the “setrons”) that are well established for clinical use. To enable us to better understand the actions of these drugs in vivo, we report the synthesis of 8-fluoropalonosetron ( 15 ) that has a binding affinity ( K i = 0.26 ± 0.05 nM) similar to the parent drug ( K i = 0.21 ± 0.03 nM). We radiolabeled 15 by nucleophilic 18 F-fluorination of an unsymmetrical diaryliodonium palonosetron precursor and achieved the radiosynthesis of 1-(methyl- 11 C )- N -granisetron ([ 11 C] 2 ) through N -alkylation with [ 11 C]CH 3 I, respectively. Both compounds [ 18 F] 15 (chemical and radiochemical purity >95%, specific activity 41 GBq/μmol) and [ 11 C] 2 (chemical and radiochemical purity ≥99%, specific activity 170 GBq/μmol) were evaluated for their utility as positron emission tomography (PET) probes. Using mouse and rat brain slices, in vitro autoradiography with both [ 18 F] 15 and [ 11 C] 2 revealed a heterogeneous and displaceable binding in cortical and hippocampal regions that are known to express 5-HT 3 receptors at significant levels. Subsequent PET experiments suggested that [ 18 F] 15 and [ 11 C] 2 are of limited utility for the PET imaging of brain 5-HT 3 receptors in vivo.
No takes yet. Share an insight, caveat, or question.
Mu et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: